AlanSGamisMDMPH

Pediatric Hematology & Oncology • Kansas City, MO

Pediatric Oncologist, Professor of Pediatrics

Join to view full profile

Dr. Gamis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gamis' full profile

Already have an account?

Office
2401 Gillham Rd
# Children
Kansas City, MO 64108
Phone+1 816-302-6808

Fax+1 816-302-9894

Summary

Dr. Alan Gamis is a pediatric hematologist/oncologist in Kansas City, MO and is affiliated with Children's Mercy Kansas City. He received his medical degree from University of Illinois College of Medicine and has been in practice 33 years. He is experienced in childhood tumors, leukemia, and pediatric hematology / oncology.

Education & Training

University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Children’s Mercy HospitalResidency, Pediatrics, 1985 - 1988
University of Missouri-Kansas City School of MedicineInternship, Internal Medicine, 1984 - 1985
University of Illinois College of MedicineClass of 1984

Certifications & Licensure

KS State Medical License 2014 - 2025
MO State Medical License 1986 - 2025
MN State Medical License 1988 - 1991
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Start of enrollment: 1999 Jun 01
Completed
Phase 3
Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.
Abdelrahman H Elsayed, Xueyuan Cao, Richard J Marrero, Nam H K Nguyen, Huiyun Wu
NPJ Precision Oncology. 2024-08-01
Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study.
Juliette Renaud, Bianca F Goemans, Franco Locatelli, Martina Pigazzi, Shelagh Redmond
Pediatric Blood & Cancer. 2024-07-01
2 citations
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
Romy E van Weelderen, Christine J Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson
Blood Advances. 2024-06-25

Abstracts/Posters

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a ChildrenÍs Onc...
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Chi...
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia _ a COG and Tpaml Study
Alan S Gamis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Children’s Mercy Kansas City Tackles the Unique Complexity of Pediatric CancerMarch 10th, 2023
Doctors, Parents Frustrated over Critical Cancer Drug ShortageOctober 18th, 2019
Shortage of Chemotherapy Drug Affecting Dozens of Kids with Cancer in KC MetroOctober 18th, 2019
Join now to see all